Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study

AIMS: To compare the pharmacokinetic (PK) and glucodynamic (GD) characteristics of ultra rapid lispro (URLi; Eli Lilly and Company, Indianapolis, Indiana), Fiasp® (Novo Nordisk, Bagsvaerd, Denmark), Humalog® (Eli Lilly and Company) and NovoRapid® (Novo Nordisk), in patients with type 1 diabetes (T1D...

Descripción completa

Detalles Bibliográficos
Autores principales: Heise, Tim, Linnebjerg, Helle, Coutant, David, LaBell, Elizabeth, Zijlstra, Eric, Kapitza, Christoph, Bue‐Valleskey, Juliana, Zhang, Qianyi, Dellva, Mary Anne, Leohr, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540588/
https://www.ncbi.nlm.nih.gov/pubmed/32436641
http://dx.doi.org/10.1111/dom.14094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540588/
https://www.ncbi.nlm.nih.gov/pubmed/32436641
http://dx.doi.org/10.1111/dom.14094

Ejemplares similares